CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 60 enrolled
Drug / intervention
Ursodeoxycholic Aciddrug
Likely dose
Ursodeoxycholic Acid 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00858858
NCT00858858N/ACompleted
CompareCT.gov

Clinical Studies on Bile Acids in Barrett's Esophagus

US Department of Veterans Affairs·interventional·Posted Mar 10, 2009·Updated Apr 30, 2015

In Brief

A clinical study evaluating Ursodeoxycholic Acid for Gastroesophageal Reflux Disease. Completed, enrolled 60 participants across 1 site.

Detailed Summary

This study has two major goals: 1. To determine the effects of bile salts on causing DNA injury and activating signaling pathways that promote growth in cells from the esophagus of patients who have gastroesophageal reflux disease (GERD) 2. To determine whether changes in bile composition induced by treating patients with a bile salt called ursodeoxycholic acid (UDCA) can alter DNA injury, signaling pathway activation and other types of damage in cells from the esophagus of patients who have GERD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux Disease
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 10, 2009
Enrollment StartMar 1, 2009
Primary CompletionMar 1, 2013
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 17.3 years ago

Interventions

Ursodeoxycholic Aciddrug

8 weeks of oral UDCA treatment 10 mg/kg qd